Chemotherapy Induced Nausea and Vomiting (CINV) Clinical Trials and Pipeline 2025: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Medication, NDA Approval, IND, Mechanism of Action, Route of Administration, Companies by DelveInsight

(Albany, United States) As per DelveInsight's assessment, globally, Chemotherapy Induced Nausea and Vomiting pipeline constitutes 8+ key companies continuously working towards developing 10+ Chemotherapy Induced Nausea and Vomiting treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Chemotherapy Induced Nausea and Vomiting Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chemotherapy Induced Nausea and Vomiting Market.

The Chemotherapy Induced Nausea and Vomiting Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for sample report @ https://www.delveinsight.com/report-store/chemotherapy-induced-nausea-and-vomiting-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key takeaways from the Chemotherapy Induced Nausea and Vomiting Pipeline Report:
• CINV Companies across the globe are diligently working toward developing novel Chemotherapy Induced Nausea and Vomiting treatment therapies with a considerable amount of success over the years.
• Chemotherapy Induced Nausea and Vomiting companies working in the treatment market are Simon Williamson Clinic, Xiamen LP Pharmaceutical, Helsinn Healthcare SA, Heron Therapeutics, and others, are developing therapies for the Chemotherapy Induced Nausea and Vomiting treatment
• Emerging Chemotherapy Induced Nausea and Vomiting therapies in the different phases of clinical trials are- Akynzeo, IV Palonosetron 0.25 mg, NEPA (300mg netupitant/0.5mg palonosetron), SUSTOL, and others are expected to have a significant impact on the Chemotherapy Induced Nausea and Vomiting market in the coming years.
• In April 2025, Helsinn Healthcare SA has announced a Multicentre, Multinational, Pharmacokinetic, Safety, and Efficacy Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC). A 2-part Study With Phase 2, Open-label, Randomised, Single-dose IV NEPA vs Fosaprepitant/Ondansetron in Single-day HEC and Repeated-dose IV NEPA in Multi-day HEC (Part I, Single Cycle) and With Phase 3, Double-blind, Randomised, Repeated-dose IV NEPA vs Fosaprepitant/Ondansetron in Multi-day HEC (Part II, Repeated Cycles)
• In March 2025, Xiamen LP Pharmaceutical Co., Ltd has announced a Randomized, Dose-ranging, Open-label, Parallel Group Study to Assess the Efficacy, Safety and Pharmacokinetics of Palonosetron HCl Buccal Film Versus IV Palonosetron 0.25 mg for the Prevention of CINV in Cancer Patients Receiving MEC
• In January 2025, Merck Sharp & Dohme LLC announced a Phase 4, Open-label, Single Arm Study to Evaluate the Safety and Tolerability of a Three-day Fosaprepitant Regimen Administered for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants Receiving Emetogenic Chemotherapy

Chemotherapy Induced Nausea and Vomiting Overview
Chemotherapy Induced Nausea and Vomiting (CINV) is one of the most distressing side effects experienced by cancer patients undergoing chemotherapy. Chemotherapy Induced Nausea and Vomiting typically occurs due to the stimulation of specific receptors in the brain and gastrointestinal tract by chemotherapeutic agents. Chemotherapy Induced Nausea and Vomiting can be classified into five types: acute, delayed, anticipatory, breakthrough, and refractory, each requiring a tailored management approach.

Chemotherapy Induced Nausea and Vomiting significantly impacts patients' quality of life, adherence to treatment, and overall therapeutic outcomes. Chemotherapy Induced Nausea and Vomiting management often involves the use of antiemetic drugs such as serotonin (5-HT3) receptor antagonists, neurokinin-1 (NK1) receptor antagonists, corticosteroids, and newer agents like olanzapine. Chemotherapy Induced Nausea and Vomiting risk depends on the type and dose of chemotherapy, individual patient susceptibility, and previous CINV experience.

Chemotherapy Induced Nausea and Vomiting prevention and control are crucial for improving patient comfort and maintaining treatment efficacy. Chemotherapy Induced Nausea and Vomiting guidelines from organizations such as ASCO and NCCN recommend prophylactic antiemetics tailored to the emetogenic potential of chemotherapy regimens. Chemotherapy Induced Nausea and Vomiting remains an important focus of supportive cancer care, with ongoing research aimed at enhancing its prevention and treatment.

Get a Free Sample PDF Report to know more about Chemotherapy Induced Nausea and Vomiting Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/chemotherapy-induced-nausea-and-vomiting-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging Chemotherapy Induced Nausea and Vomiting Drugs Under Different Phases of Clinical Development Include:
• Akynzeo: Simon Williamson Clinic
• IV Palonosetron 0.25 mg: Xiamen LP Pharmaceutical
• NEPA (300mg netupitant/0.5mg palonosetron): Helsinn Healthcare SA
• SUSTOL: Heron Therapeutics

Chemotherapy Induced Nausea and Vomiting Route of Administration
Chemotherapy Induced Nausea and Vomiting pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Chemotherapy Induced Nausea and Vomiting Molecule Type
Chemotherapy Induced Nausea and Vomiting Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Chemotherapy Induced Nausea and Vomiting Pipeline Therapeutics Assessment
• Chemotherapy Induced Nausea and Vomiting Assessment by Product Type
• Chemotherapy Induced Nausea and Vomiting By Stage and Product Type
• Chemotherapy Induced Nausea and Vomiting Assessment by Route of Administration
• Chemotherapy Induced Nausea and Vomiting By Stage and Route of Administration
• Chemotherapy Induced Nausea and Vomiting Assessment by Molecule Type
• Chemotherapy Induced Nausea and Vomiting by Stage and Molecule Type

DelveInsight's Chemotherapy Induced Nausea and Vomiting Report covers around 10+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Chemotherapy Induced Nausea and Vomiting product details are provided in the report. Download the Chemotherapy Induced Nausea and Vomiting pipeline report to learn more about the emerging Chemotherapy Induced Nausea and Vomiting therapies - https://www.delveinsight.com/report-store/chemotherapy-induced-nausea-and-vomiting-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key companies in the Chemotherapy Induced Nausea and Vomiting Therapeutics Market include:
Key companies developing therapies for Chemotherapy Induced Nausea and Vomiting are - Helsinn Healthcare SA, Acacia Pharma, Camurus, Benuvia Therapeutics, Aphios Corporation, Zhuhai Beihai Biotech Co., Ltd., and others.

Chemotherapy Induced Nausea and Vomiting Pipeline Analysis:
The Chemotherapy Induced Nausea and Vomiting pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Chemotherapy Induced Nausea and Vomiting with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chemotherapy Induced Nausea and Vomiting Treatment.
• Chemotherapy Induced Nausea and Vomiting key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Chemotherapy Induced Nausea and Vomiting Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chemotherapy Induced Nausea and Vomiting market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Chemotherapy Induced Nausea and Vomiting drugs and therapies - https://www.delveinsight.com/sample-request/chemotherapy-induced-nausea-and-vomiting-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Chemotherapy Induced Nausea and Vomiting Pipeline Market Drivers
Increasing cancer prevalence, unmet medical need, Focus on patient-centric care, Technological advancements, Regulatory incentives, are some of the important factors that are fueling the Chemotherapy Induced Nausea and Vomiting Market.

Chemotherapy Induced Nausea and Vomiting Pipeline Market Barriers
However, Complex etiology, Variability in patient response, Adverse effects, Clinical trial design challenges, Competition with existing therapies, Reimbursement considerations, and other factors are creating obstacles in the Chemotherapy Induced Nausea and Vomiting Market growth.

Scope of Chemotherapy Induced Nausea and Vomiting Pipeline Drug Insight
• Coverage: Global
• Key Chemotherapy Induced Nausea and Vomiting Companies: Simon Williamson Clinic, Xiamen LP Pharmaceutical, Helsinn Healthcare SA, Heron Therapeutics, and others
• Key Chemotherapy Induced Nausea and Vomiting Therapies: Akynzeo, IV Palonosetron 0.25 mg, NEPA (300mg netupitant/0.5mg palonosetron), SUSTOL, and others
• Chemotherapy Induced Nausea and Vomiting Therapeutic Assessment: Chemotherapy Induced Nausea and Vomiting current marketed and Chemotherapy Induced Nausea and Vomiting emerging therapies
• Chemotherapy Induced Nausea and Vomiting Market Dynamics: Chemotherapy Induced Nausea and Vomiting market drivers and Chemotherapy Induced Nausea and Vomiting market barriers

Request for Sample PDF Report for Chemotherapy Induced Nausea and Vomiting Pipeline Assessment and clinical trials - https://www.delveinsight.com/sample-request/chemotherapy-induced-nausea-and-vomiting-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Chemotherapy Induced Nausea and Vomiting Report Introduction
2. Chemotherapy Induced Nausea and Vomiting Executive Summary
3. Chemotherapy Induced Nausea and Vomiting Overview
4. Chemotherapy Induced Nausea and Vomiting- Analytical Perspective In-depth Commercial Assessment
5. Chemotherapy Induced Nausea and Vomiting Pipeline Therapeutics
6. Chemotherapy Induced Nausea and Vomiting Late Stage Products (Phase II/III)
7. Chemotherapy Induced Nausea and Vomiting Mid Stage Products (Phase II)
8. Chemotherapy Induced Nausea and Vomiting Early Stage Products (Phase I)
9. Chemotherapy Induced Nausea and Vomiting Preclinical Stage Products
10. Chemotherapy Induced Nausea and Vomiting Therapeutics Assessment
11. Chemotherapy Induced Nausea and Vomiting Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Chemotherapy Induced Nausea and Vomiting Key Companies
14. Chemotherapy Induced Nausea and Vomiting Key Products
15. Chemotherapy Induced Nausea and Vomiting Unmet Needs
16 . Chemotherapy Induced Nausea and Vomiting Market Drivers and Barriers
17. Chemotherapy Induced Nausea and Vomiting Future Perspectives and Conclusion
18. Chemotherapy Induced Nausea and Vomiting Analyst Views
19. Appendix
20. About DelveInsight

Trending Reports:
• Angina Pectoris Market: https://www.delveinsight.com/report-store/angina-angina-pectoris-market
• Anorectal Malformation Market: https://www.delveinsight.com/report-store/anorectal-malformation-market
• Anovulation Market: https://www.delveinsight.com/report-store/anovulation-market
• Anterior Cruciate Ligament Injuries Market: https://www.delveinsight.com/report-store/anterior-cruciate-ligament-injuries-epidemiology-forecast
• Antibody Mediated Rejection Market: https://www.delveinsight.com/report-store/antibody-mediated-rejection-market
• Antiphospholipid Syndrome Aps Market: https://www.delveinsight.com/report-store/antiphospholipid-syndrome-aps-market
• Arthroscopic Shavers Market: https://www.delveinsight.com/report-store/arthroscopic-shavers-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Aspergillosis Market: https://www.delveinsight.com/report-store/aspergillosis-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Atypical Teratoid Rhabdoid Tumors Market: https://www.delveinsight.com/report-store/atypical-teratoid-rhabdoid-tumors-market
• Hyperhidrosis Market: https://www.delveinsight.com/report-store/axillary-hyperhidrosis-ahh-market
• Bacterial Pyogenic Meningitis Market: https://www.delveinsight.com/report-store/bacterial-pyogenic-meningitis-market
• Becker Muscular Dystrophy Market: https://www.delveinsight.com/report-store/becker-muscular-dystrophy-market
• Bile Duct Neoplasm Market: https://www.delveinsight.com/report-store/bile-duct-cancer-market
• Bipolar Depression Market: https://www.delveinsight.com/report-store/bipolar-disorder-manic-depression-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Bradycardia Treatment Devices Market: https://www.delveinsight.com/report-store/bradycardia-treatment-devices-market
• Bronchopulmonary Dysplasia Market: https://www.delveinsight.com/report-store/bronchopulmonary-dysplasia-market
• Bunion Market: https://www.delveinsight.com/report-store/bunion-market
• Cancer Anorexia Market: https://www.delveinsight.com/report-store/cancer-anorexia-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Cardiotoxicity Market: https://www.delveinsight.com/report-store/cardiotoxicity-market
• Carpal Tunnel Syndrome Market: https://www.delveinsight.com/report-store/carpal-tunnel-release-system-market
• Catheter-related Bloodstream Infections Market: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-crbsi-market-size-analysis

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.